Molecular Predictors of Radiation Resistance


Unknown Sites

What is the purpose of this trial?

Enhanced sensitivity to radiation has been identified as a characteristic of non-small cell lung tumors with EGFR kinase domain mutations. We have confirmed this in vitro finding through an analysis of clinical outcomes after radiation therapy. Pathology from tumors treated with radiation therapy that recurred locally will be analyzed for molecular abnormalities. The techniques used will include standard pathologic review, immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), and exome sequencing. This analysis is important to the field of radiation oncology as it suggests that a tumor genotype can predict outcomes to radiation therapy. We now hypothesize that analysis of radioresistant tumors will identify key molecular characteristics that regulate or modify the radiation response. Successful completion of this study may provide new strategies to risk stratify patients for radiation therapy or suggest novel approaches for improving the efficacy of radiation therapy.

Participation Guidelines


Click here for detailed information about who can participate in this trial.

Yale University School of Medicine
Last Updated:
Study HIC#: